These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34779495)

  • 1. Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance.
    Tak E; Kim M; Cho Y; Choi S; Kim J; Han B; Kim HD; Jang CS; Kim JE; Hong YS; Kim SY; Kim TW
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34779495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of
    Georgiou A; Stewart A; Cunningham D; Banerji U; Whittaker SR
    Mol Cancer Res; 2020 Jun; 18(6):835-846. PubMed ID: 32098826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.
    Mei Z; Shao YW; Lin P; Cai X; Wang B; Ding Y; Ma X; Wu X; Xia Y; Zhu D; Shu Y; Fu Z; Gu Y
    BMC Cancer; 2018 Apr; 18(1):479. PubMed ID: 29703253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
    Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
    Song K; Lu H; Jin L; Wang K; Guo W; Zheng H; Li K; He C; You T; Fu Y; Yang J; Zhao W; Guo Z
    FEBS J; 2020 Dec; 287(23):5236-5248. PubMed ID: 32216031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS.
    Ishida T; Ishii Y; Tsuruta M; Okabayashi K; Akimoto S; Koishikawa K; Hasegawa H; Kitagawa Y
    Oncol Rep; 2017 Aug; 38(2):926-932. PubMed ID: 28656305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.
    Jia YT; Yang DH; Zhao Z; Bi XH; Han WH; Feng B; Zhi J; Gu B; Duan Z; Wu JH; Ju YC; Wang MX; Li ZX
    Curr Cancer Drug Targets; 2018; 18(3):278-286. PubMed ID: 28359236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer.
    Arai H; Elliott A; Millstein J; Xiu J; Ou FS; Innocenti F; Wang J; Battaglin F; Jayachandran P; Kawanishi N; Soni S; Zhang W; Sohal D; Goldberg RM; Hall MJ; Scott AJ; Khushman M; Hwang JJ; Lou E; Weinberg BA; Lockhart AC; Shields AF; Abraham JP; Magee D; Stafford P; Zhang J; Venook AP; Korn WM; Lenz HJ
    Oncogene; 2022 Jan; 41(2):260-267. PubMed ID: 34728807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
    Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
    Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines.
    Dahan L; Sadok A; Formento JL; Seitz JF; Kovacic H
    Br J Pharmacol; 2009 Sep; 158(2):610-20. PubMed ID: 19732064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.
    Arena S; Bellosillo B; Siravegna G; Martínez A; Cañadas I; Lazzari L; Ferruz N; Russo M; Misale S; González I; Iglesias M; Gavilan E; Corti G; Hobor S; Crisafulli G; Salido M; Sánchez J; Dalmases A; Bellmunt J; De Fabritiis G; Rovira A; Di Nicolantonio F; Albanell J; Bardelli A; Montagut C
    Clin Cancer Res; 2015 May; 21(9):2157-66. PubMed ID: 25623215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
    Woodfield SE; Zhang L; Scorsone KA; Liu Y; Zage PE
    BMC Cancer; 2016 Mar; 16():172. PubMed ID: 26925841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
    Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
    Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
    Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linking FOXO3, NCOA3, and TCF7L2 to Ras pathway phenotypes through a genome-wide forward genetic screen in human colorectal cancer cells.
    Kundu S; Ali MA; Handin N; Padhan N; Larsson J; Karoutsou M; Ban K; Wiśniewski JR; Artursson P; He L; Hellström M; Sjöblom T
    Genome Med; 2018 Jan; 10(1):2. PubMed ID: 29301589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDE4DIP contributes to colorectal cancer growth and chemoresistance through modulation of the NF1/RAS signaling axis.
    Pan R; Dai J; Liang W; Wang H; Ye L; Ye S; Lin Z; Huang S; Xiong Y; Zhang L; Lu L; Wang O; Shen X; Liao W; Lu X
    Cell Death Dis; 2023 Jun; 14(6):373. PubMed ID: 37355626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.
    Sangha N; Wu R; Kuick R; Powers S; Mu D; Fiander D; Yuen K; Katabuchi H; Tashiro H; Fearon ER; Cho KR
    Neoplasia; 2008 Dec; 10(12):1362-72, following 1372. PubMed ID: 19048115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
    Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
    JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.